Researchers estimate that semaglutide 2.4 mg is not cost-effective for secondary CVD prevention for patients with overweight or obesity without diabetes, according to an Australian study. Ella Zomer, BBiomedSc, PhD, senior research fellow at Monash University School of Public Health and Preventive Medicine in Melbourne, Australia, and colleagues estimated that the cost of semaglutide 2.4 mg
Richard Smith is a contributing writer for various publications including Healio and Daily News-Sun. With a wide range of topics covered, Richard's articles touch on subjects such as healthcare, education, sports, and community news. His work has also been featured in notable publications such as BMJ, TechCrunch, The Lancet, and Le Monde.